Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;69(4):e70009.
doi: 10.1111/aas.70009.

Preferences for thromboprophylaxis in the intensive care unit: An international survey

Èmese Robin Hélène Heijkoop  1 Frederik Keus  2 Morten Hylander Møller  3   4 Anders Perner  3 Matthew Morgan  5 Adel Abdelhadi  6 Nehad Nabeel Mohamed Al Shirawi  7 Abdulrahman A Al-Fares  8   9 Fayez Alshamsi  10 Prakkash Parangi Ananthan  11 Anne Sofie Andreasen  12 Matthew H Anstey  13 Yaseen M Arabi  14 Tayyba Naz Aslam  15   16 Antony George Attokaran  17 Morten H Bestle  4   18 Neeraj Bhadange  19   20 Annika Reintam Blaser  21   22 Anne Craveiro Brøchner  23 Maria Cronhjort  24 Wojciech Dąbrowski  25 Ashraf Elhoufi  26 Begum Ergan  27 Ricard Ferrer  28   29   30 Ross Freebairn  31   32 Tomoko Fujii  33 Massimiliano Greco  34   35 Frank M P van Haren  36   37 Thomas Hildebrandt  38 Peter Buhl Hjortrup  39 Kwok M Ho  40 Sandra Jonmarker  41   42 Peter Kruger  43 Manu L N G Malbrain  25 Jihad Mallat  44 Prashanti Marella  45 Mervyn Mer  46 Tine Sylvest Meyhoff  47 Marek Nalos  48 Mohamed Nassef  49 Rania Omar  50 Sam Orde  51   52 Marlies Ostermann  53 David Pilcher  54 Lone Musaeus Poulsen  55 Sumeet Rai  56 Kiran Shekar  57   58 Martin Siegemund  59   60 Martin Ingi Sigurdsson  61   62 Bodil Steen Rasmussen  63   64 Thomas Tværmose Troelsen  65 Mette Krag  4   66 Paul Young  67   68   69   70 Karina Meijer  71 Ruben Julius Eck  72
Affiliations

Preferences for thromboprophylaxis in the intensive care unit: An international survey

Èmese Robin Hélène Heijkoop et al. Acta Anaesthesiol Scand. 2025 Apr.

Abstract

Background: Venous thromboembolism (VTE) is a frequent complication in critically ill patients, who often have multiple risk factors. Pharmacological thromboprophylaxis is widely applied to lower this risk, but guidelines lack dosing recommendations.

Objective: This survey aims to assess current thromboprophylaxis preferences and willingness to participate in future randomized clinical trials (RCTs) on this topic.

Method: We conducted an international online survey between February and May 2023 among intensive care unit (ICU) physicians, including 16 questions about preferences in relation to thromboprophylaxis and preferences on topics for a future RCT. The survey was distributed through the network of the Collaboration for Research in Intensive Care.

Results: A total of 715 physicians from 170 ICUs in 23 countries contributed information, with a mean response rate of 36%. In most ICUs, both pharmacological (n = 166, 98%) and mechanical thromboprophylaxis (n = 143, 84%) were applied. A total of 36 pharmacological thromboprophylaxis regimens were reported. Use of low-molecular-weight heparin (LMWH) was most common (n = 149 ICUs, 87%), followed by subcutaneous unfractionated heparin (n = 44 ICUs, 26%). Seventy-five percent of physicians indicated that they used enoxaparin 40 mg (4000 IU), dalteparin 5000 IU, or tinzaparin 4500 IU once daily, whereas 25% reported the use of 16 other LMWH type and dose combinations. Dose adjustment according to weight was common (78 ICUs, 46%). Participants perceived high variation in the application of thromboprophylaxis and were willing to consider an alternative LMWH type (n = 542, 76%) or dose (n = 538, 75%) in the context of an RCT.

Conclusion: LMWH was the preferred agent for thromboprophylaxis in critically ill patients. There was considerable variation in the application of LMWH for prophylaxis, reflected by the use of different types, doses, and dosing strategies. Most physicians would be willing to participate in an RCT on thromboprophylaxis.

Editorial comment: This survey demonstrates current patterns in implementation preferences for critically ill patients. While there is one approach and drug that is commonly preferred, these findings show that there is some variation in practice.

Keywords: ICU; survey; thromboprophylaxis.

PubMed Disclaimer

References

REFERENCES

    1. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical‐surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005;33(7):1565‐1571.
    1. Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19(1):1‐9. doi:10.1186/s13054‐015‐1003‐9
    1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet. 1999;353(9162):1386‐1389.
    1. Kahn SR. How I treat postthrombotic syndrome. Blood. 2009;114(21):4624‐4631. doi:10.1182/blood‐2009‐07‐199174
    1. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3(7):564‐567.

MeSH terms

Substances

LinkOut - more resources